Related Post
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - March 1st, 2025
- TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis - March 1st, 2025
- Ultimovacs ASA: Approval and publication of prospectus - March 1st, 2025
- Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous... - March 1st, 2025
- Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting... - March 1st, 2025
- InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - March 1st, 2025
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - March 1st, 2025
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - March 1st, 2025
- ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - March 1st, 2025
- SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company - March 1st, 2025
- CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - March 1st, 2025
- Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older - March 1st, 2025
- Orion Corporation: Managers’ transactions – Outi Vaarala - March 1st, 2025
- Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - March 1st, 2025
- Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® - March 1st, 2025
- Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination... - March 1st, 2025
- Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - March 1st, 2025
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - March 1st, 2025
- Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - March 1st, 2025
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - March 1st, 2025
- Biongevity Celebrates Success of World’s First Longevity Fitness Challenge in UAE & Announces Longevity Health Plans - February 27th, 2025
- Renovaro Announces $15 million in Equity Committed - February 27th, 2025
- Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading... - February 27th, 2025
- AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - February 27th, 2025
- Shuttle Pharma Provides Corporate Update and Reports 2024 Results - February 27th, 2025
- Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - February 27th, 2025
- Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine - February 27th, 2025
- Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results - February 27th, 2025
- Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal... - February 27th, 2025
- scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences - February 27th, 2025
- Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - February 27th, 2025
- Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - February 27th, 2025
- Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - February 27th, 2025
- Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences - February 27th, 2025
- Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference - February 27th, 2025
- Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - February 27th, 2025
- Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - February 27th, 2025
- Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - February 27th, 2025
- Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter - February 27th, 2025
- Certara Reports Fourth Quarter 2024 Financial Results - February 27th, 2025
- Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer - February 25th, 2025
- Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the... - February 25th, 2025
- Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 - February 25th, 2025
- Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference - February 25th, 2025
- BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - February 25th, 2025
- atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - February 25th, 2025
- Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - February 25th, 2025
- Travere Therapeutics to Participate at Upcoming Investor Conferences - February 25th, 2025
- Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting - February 25th, 2025
- Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025 - February 25th, 2025
- Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma - February 25th, 2025
- Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine - February 25th, 2025
- argenx to Present at TD Cowen 45th Annual Healthcare Conference - February 25th, 2025
- PCI Biotech: Invitation to preliminary full-year 2024 results presentation - February 25th, 2025
- Opdateret finanskalender 2025 - February 25th, 2025
- CancerVax Announces Successful Tests of its Smart mRNA Technology - February 25th, 2025
- ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2... - February 25th, 2025
- Notice to the Annual General Meeting of Orion Corporation - February 25th, 2025
- Orion Group Financial Statement Release January–December 2024 - February 25th, 2025
- Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons - February 25th, 2025
- Change to the Executive Leadership Team - February 23rd, 2025
- Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards - February 23rd, 2025
- Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC - February 23rd, 2025
- Seer to Participate in the TD Cowen 45th Annual Health Care Conference - February 23rd, 2025
- Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - February 23rd, 2025
- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - February 23rd, 2025
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial... - February 23rd, 2025
- Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - February 23rd, 2025
- Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call - February 23rd, 2025
- Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - February 23rd, 2025
- Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - February 23rd, 2025
- Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel... - February 23rd, 2025
- Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration - February 23rd, 2025
- Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG) - February 23rd, 2025
- Ipsen S.A. publishes its 2024 consolidated financial statements - February 23rd, 2025
- Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - February 23rd, 2025
- eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - February 23rd, 2025
- Fortrea to Add Erin L. Russell to Board of Directors - February 23rd, 2025
- Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative... - February 23rd, 2025
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - February 23rd, 2025
Recent Comments